Gwiazda Roberto, Lucchini Roberto, Smith Donald
Department of Environmental Toxicology, University of California, Santa Cruz, California 95064, USA.
J Toxicol Environ Health A. 2007 Apr 1;70(7):594-605. doi: 10.1080/10937400600882897.
The adequacy of existing animal studies to understand the effects of chronic low-level manganese exposures in humans is unclear. Here, a collection of subchronic to chronic rodent and nonhuman primate studies was evaluated to determine whether there is a consistent dose-response relationship among studies, whether there is a progression of effects with increasing dose, and whether these studies are adequate for evaluating the neurotoxicity of chronic low-level manganese exposures in humans. Neurochemical and behavioral effects were compared along the axis of estimated internal cumulative manganese dose, independent of the route of exposure. In rodents, motor effects emerged at cumulative doses below those where occupationally exposed humans start to show motor deficits. The main neurochemical effects in rodents were an increase in striatal gamma-aminobutyric acid (GABA) concentration throughout the internal cumulative dose range of 18 to 5300 mg Mn/kg but a variable effect on striatal dopamine concentration emerging at internal cumulative doses above approximately 200 mg Mn/kg. Monkey studies showed motor deficits and effects on the globus pallidus at relatively low doses and consistent harmful effects on both the globus pallidus and the caudate and putamen at higher doses (> 260 mg Mn/kg). Internal cumulative manganese doses of animal studies extend more than two orders of magnitude (< 1 to 5300 mg Mn/kg) above the doses at which occupationally exposed humans show neurological dysfunction (10-15 mg Mn/kg). Since the animal data indicate that manganese neurotoxicity may be different at low compared to elevated exposures, most existing animal model studies might be of limited relevance for the risk assessment of chronic low-level manganese exposure to humans.
现有动物研究对于理解慢性低水平锰暴露对人类影响的充分性尚不清楚。在此,对一系列从亚慢性到慢性的啮齿动物和非人灵长类动物研究进行了评估,以确定各研究之间是否存在一致的剂量反应关系、效应是否随剂量增加而进展,以及这些研究是否足以评估慢性低水平锰暴露对人类的神经毒性。沿着估计的体内累积锰剂量轴比较神经化学和行为效应,而不考虑暴露途径。在啮齿动物中,运动效应出现在累积剂量低于职业暴露人类开始出现运动功能缺陷的剂量时。啮齿动物的主要神经化学效应是,在18至5300毫克锰/千克的体内累积剂量范围内,纹状体γ-氨基丁酸(GABA)浓度增加,但在体内累积剂量高于约200毫克锰/千克时,对纹状体多巴胺浓度的影响则有所不同。猴子研究表明,在相对低剂量时出现运动功能缺陷和对苍白球的影响,在较高剂量(>260毫克锰/千克)时,对苍白球以及尾状核和壳核均有持续的有害影响。动物研究的体内累积锰剂量比职业暴露人类出现神经功能障碍的剂量(10 - 15毫克锰/千克)高出两个多数量级(<1至5300毫克锰/千克)。由于动物数据表明,与高暴露相比,低水平锰的神经毒性可能不同,因此大多数现有的动物模型研究对于慢性低水平锰暴露对人类风险评估的相关性可能有限。